STRS Ohio’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

STRS Ohio’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,800	Closed	-$94.8K	–	2009
2016 Q4	$83K	Sell	10,800 -12,300	-53%	-$113K	﹤0.01%	1700
2016 Q3	$264K	Sell	23,100 -900	-4%	-$10.5K	﹤0.01%	1492
2016 Q2	$295K	Buy	24,000 +13,300	+124%	+$161K	﹤0.01%	1470
2016 Q1	$108K	Sell	10,700 -9,200	-46%	-$108K	﹤0.01%	1644
2015 Q4	$448K	Hold	19,900	–	–	﹤0.01%	1324
2015 Q3	$330K	Hold	19,900	–	–	﹤0.01%	1410
2015 Q2	$447K	Sell	19,900 -7,800	-28%	-$192K	﹤0.01%	1361
2015 Q1	$714K	Sell	27,700 -5,900	-18%	-$150K	﹤0.01%	1022
2014 Q4	$731K	Buy	33,600 +2,253	+7%	+$46.2K	﹤0.01%	1011
2014 Q3	$593K	Buy	31,347 +27,347	+684%	+$550K	﹤0.01%	1117
2014 Q2	$93K	Buy	+4,000	New	+$98.8K	﹤0.01%	1564
2014 Q1	–	Sell	-1,900	Closed	-$64K	–	1836
2013 Q4	$56K	Sell	1,900 -200	-10%	-$3.66K	﹤0.01%	1629
2013 Q3	$32K	Buy	+2,100	New	+$38.9K	﹤0.01%	1764

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

STRS Ohio's OMED Position: Q1 2017 in Review

STRS Ohio sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2017, closing a stake of 10,800 shares — an estimated $94.8K sold.

STRS Ohio first reported a position in OMED in Q3 2013 and held it in 13 quarters. The position peaked at $731K in Q4 2014. 85 funds tracked by Wall St. Rank hold OMED as of Q1 2017.

STRS Ohio reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
STRS Ohio sold 10,800 OncoMed Pharmaceuticals, Inc. shares in Q1 2017, an estimated $94.8K.
STRS Ohio first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 13 quarters.
STRS Ohio's OncoMed Pharmaceuticals, Inc. position peaked at $731K in Q4 2014.
85 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2017.

Based on STRS Ohio's 13F filing for Q1 2017, filed 26 Apr 2017.